Medical Developments International Ltd
ASX:MVP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (1.6), the stock would be worth AU$0.59 (29% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.3 | AU$0.46 |
0%
|
| 3-Year Average | 1.6 | AU$0.59 |
+29%
|
| 5-Year Average | 2.3 | AU$0.83 |
+79%
|
| Industry Average | 18 | AU$6.49 |
+1 311%
|
| Country Average | 4.1 | AU$1.47 |
+220%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
AU$46.2m
|
/ |
Jan 2026
AU$40.6m
|
= |
|
|
AU$46.2m
|
/ |
Jun 2026
AU$44m
|
= |
|
|
AU$46.2m
|
/ |
Jun 2027
AU$48.3m
|
= |
|
|
AU$46.2m
|
/ |
Jun 2028
AU$52.9m
|
= |
|
|
AU$46.2m
|
/ |
Jun 2029
AU$58.9m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Medical Developments International Ltd
ASX:MVP
|
51.8m AUD | 1.3 | -118.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 13.5 | 42.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 5.8 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 4.9 | 28.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 4.3 | 15.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 5 | 20.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.9 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 2.4 | 19.7 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 2.5 | 17.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.7 |
| Median | 4.1 |
| 70th Percentile | 11.8 |
| Max | 1 679 509.2 |
Other Multiples
Medical Developments International Ltd
Glance View
Medical Developments International Ltd. engages in the manufacture and distribution of pharmaceutical drugs, medical, and veterinary equipment. The company is headquartered in Melbourne, Victoria and currently employs 68 full-time employees. The company went IPO on 2003-12-15. The firm is focused on manufacturing and distributing pharmaceutical drugs, and medical and veterinary equipment. The firm operates through three segments: Pharmaceuticals, Medical Devices and Veterinary Products. The Pharmaceuticals segment is engaged in the sale of Penthrox primarily within Australia, New Zealand, Europe and the United Kingdom, and some sales in the Middle East, Asia and South Africa. The Medical Devices segment is engaged in the sale of medical devices, particularly the Space Chamber and Breath-Alert PeakFlow meters, primarily within Australia, the United Kingdom/Europe, North America, and some sales in Asia and New Zealand. The Veterinary Products segment is engaged in the sale of veterinary products within Australia, Europe, and Asia.
